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Objectives: The degree of overdiagnosis due to lung cancer screening in the general US population remains
unknown. Estimates may be inﬂuenced by the method used and by decreasing smoking trends, which reduce
lung cancer risk and screening eligibility over time. Therefore, we aimed to estimate the degree of overdiagnosis
due to lung cancer screening in the general US population, using three distinct methods.
Material and methods: The MISCAN-Lung model was used to project lung cancer incidence and overdiagnosis in
the general US population between 2018–2040, assuming perfect adherence to the United States Preventive Task
Force recommendations. MISCAN-Lung was calibrated to the NLST and PLCO trials and incorporates birth-
cohort-speciﬁc smoking trends and life expectancies. We estimated overdiagnosis using the cumulative excess-
incidence approach, the annual excess-incidence approach, and the microsimulation approach.
Results: Using the cumulative excess-incidence approach, 10.5 % of screen-detected cases were overdiagnosed in
the 1950 birth-cohort compared to 5.9 % in the 1990 birth-cohort. Incidence peaks and drops due to screening
were larger for older birth-cohorts than younger birth-cohorts. In the general US population, these diﬀering
incidence peaks and drops across birth-cohorts overlap. Therefore, annual excess-incidence would be absent
between 2029–2040, suggesting no overdiagnosis occurs. Using the microsimulation approach, overdiagnosis
among screen-detected cases increased from 7.1 % to 9.5 % between 2018–2040, while overdiagnosis among all
lung cancer cases decreased from 3.7 % to 1.4 %.
Conclusion: Overdiagnosis studies should use appropriate methods to account for trends in background risk and
screening eligibility in the general population. Estimates from randomized trials, based on the cumulative ex-
cess-incidence approach, are not generalizable to the general population. The annual excess-incidence approach
does not account for trends in background risk and screening eligibility, and falsely suggests no overdiagnosis
occurs in the general population. Using the microsimulation approach, overdiagnosis was limited but not nil.
Overdiagnosis increased among screen-detected cases, while overdiagnosis among all cases decreased.
1. Introduction
Overdiagnosis is considered to be one of the main harms of cancer
screening, and is typically deﬁned as a screen-detected cancer that
would not have become symptomatic during an individual’s lifetime
[1]. There are two ways overdiagnosis can happen. First, a patient with
a progressive screen-detected cancer may die of other causes before
their cancer would have progressed to a point at which it would cause
symptoms (i.e. before clinical presentation). This becomes more likely
when the chances of dying from competing causes are higher, for ex-
ample when screening elderly persons [2] or those with many co-
morbidities. Second, some screen-detected cancers may not be pro-
gressive (i.e. indolent or regressing), and would thereby never reach a
point at which they would cause symptoms. In both cases, it is im-
possible to determine whether an individual screen-detected case has
been overdiagnosed.
There are several methods for estimating overdiagnosis [3]. A
commonly used method is the cumulative excess-incidence approach, in
which the diﬀerence in cumulative incidence between a screened group
and a matched control group is attributed to overdiagnosis. Several
studies used this approach to estimate the degree of overdiagnosis in
low-dose computed tomography screening for lung cancer. Using data
from the National Lung Screening Trial, Patz et al. reported that 18.5 %
of screen-detected lung cancers in the low-dose computed tomography
arm were overdiagnosed at 7 years of follow-up [4]. The Danish Lung
Screening Trial reported that 67.2 % of screen-detected cancers were
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overdiagnosed at 11 years of follow-up [5]. Finally, researchers from
the ITALUNG trial reported no overdiagnosis at 9 years of follow-up
[6].
The variation in overdiagnosis estimates between these randomized
trials has been suggested to be due to several factors, including a dif-
ferent number of screening rounds and diﬀerences in baseline lung
cancer risk [7]. The number of screening rounds per participant would
be much higher in a continuous population screening program. On the
other hand, the background lung cancer risk (and screening eligibility)
in the population has been shown to decrease over time, as younger
birth-cohorts smoke less [8]. Finally, while all randomized trial esti-
mates used the cumulative excess-incidence approach, this approach
should not be used in a continuous screening program in the general
population [9]. Using other methods may also lead to diﬀerent esti-
mates [10]. Consequently, it remains uncertain whether the published
estimates of lung cancer overdiagnosis are generalizable to a con-
tinuous screening program in the general population. Therefore, we
used three distinct methods to estimate the degree of lung cancer
overdiagnosis in the general US population when fully implementing a
continuous lung cancer screening program in 2018.
2. Material and methods
2.1. MISCAN-Lung model
Although the United States Preventive Task Force (USPSTF) has
recommended lung cancer screening in the United States since 2013
[11], current uptake is limited [12]. Consequently, comprehensive data
on lung cancer incidence and overdiagnosis in a continuous screening
program are currently not available. Therefore, we used the MIcro-
simulation SCreening ANalysis Lung (MISCAN-Lung) model to project
future lung cancer incidence and overdiagnosis in the presence and
absence of screening.
MISCAN-Lung uses the National Cancer Institute's Smoking History
Generator [8] to generate sex and birth-cohort speciﬁc life histories,
including smoking histories and non-lung cancer speciﬁc causes of
death (corrected for smoking behavior). The generated smoking his-
tories determine the chance of developing preclinical lung cancer.
When preclinical lung cancer develops, it can progress to more ad-
vanced preclinical stages. At each of these stages, the preclinical cancer
can be either clinically detected or screen-detected. For each individual,
full life histories are generated in the presence and absence of
screening. Key model parameters, such as the mean histology and sex-
speciﬁc duration in each stage (i.e. the natural history), and the stage
and histology-speciﬁc screening test sensitivity, have been calibrated to
data from the National Lung Screening Trial and the Prostate, Lung,
Colorectal and Ovarian Cancer Screening Trial. Details of model cali-
bration have been described in previous publications [13,14]. The
model was previously used to inform the USPSTF on the lung cancer
screening policy with the optimal ratio of beneﬁts and harms [11,15].
2.2. Projecting incidence
We used MISCAN-Lung to project lung cancer incidence in the US
population in the absence and presence of screening. First, we simu-
lated histology, stage, age, and sex-speciﬁc lung cancer incidence rates
for each individual birth-cohort from 1916 to 2005 (i.e. persons aged
35–99 in years 2015–2040). Thereby, we account for diﬀerent smoking
trends and life-expectancies in the evaluated population. Next, we used
the age and sex-speciﬁc Census population projections [16] to convert
the annual incidence rates for each birth-cohort to cohort-speciﬁc
Census-adjusted annual incidence counts. Finally, we aggregated these
Census-adjusted annual incidence counts across all cohorts, forming the
Census-adjusted annual incidence count for the general US population.
In the screening scenario, we assumed perfect adherence to the USPSTF
recommendations between 2018–2040 (i.e. annual screening of those
aged 55–80 with a smoking history of at least 30 pack-years, that
currently smoke or quit less than 15 years ago).
2.3. Estimating overdiagnosis
We used three distinct methods to estimate overdiagnosis: the cu-
mulative excess-incidence approach, the annual excess-incidence ap-
proach, and the microsimulation approach. The cumulative excess-in-
cidence approach subtracts the cumulative incidence in the absence of
screening after a certain period of follow-up from the cumulative in-
cidence in the presence of screening, and attributes this diﬀerence to
overdiagnosis. This approach provides an unbiased estimate of over-
diagnosis in a closed cohort with a limited number of screens and
suﬃcient follow-up [3,9]. We assume that the eﬀect of radiation ex-
posure due to LDCT screening on lung cancer incidence was negligible
[15,17]. Therefore, we used this approach to estimate overdiagnosis in
several separate US birth-cohorts with a lifetime follow-up. As the
number of individuals diﬀers per birth-cohort, overdiagnosis using the
cumulative excess-incidence approach was expressed as the rate of
overdiagnosed cases per 100,000 persons in the cohort alive in 2015.
Also, we expressed overdiagnosis as the lifetime percentage of screen-
detected cases that would be overdiagnosed, calculated by dividing the
rate of overdiagnosed cases by the rate of screen-detected cases. Finally,
we expressed overdiagnosis as the lifetime percentage of all lung cancer
cases that would be overdiagnosed, calculated by dividing the rate of
overdiagnosed cases by the cumulative incidence rate in the presence of
screening.
In a continuous screening program in the general population, the
annual excess-incidence should be used instead of the cumulative ex-
cess-incidence [9]. The underlying principle is that in a continuous
screening program in the general population, new persons will receive
their ﬁrst screening at the end of a chosen follow-up period, which
would bias the cumulative excess-incidence approach. In each calendar
year, an increased incidence due to early detection is partly compen-
sated by a drop in incidence among individuals that are no longer eli-
gible. In the annual excess-incidence approach, incidence in the ab-
sence of screening is therefore subtracted from incidence in the
presence of screening for each calendar year, and this diﬀerence is at-
tributed to overdiagnosis. This approach should provide an unbiased
overdiagnosis estimate after waiting until screening uptake stabilizes
plus the longest preclinical duration [9,18]. A recent analysis suggests
that the lead time of screen-detected lung cancers in the National Lung
Screening Trial can be as long as 9 years [19]. Therefore, we used the
annual excess-incidence approach to estimate the Census-adjusted an-
nual number of overdiagnosed cases between 2027 (i.e. 2018 plus 9
years of lead time) and 2040 in the general US population. Over-
diagnosis was also expressed as the annual percentage of screen-de-
tected cases that would be overdiagnosed, calculated by dividing the
Census-adjusted excess-incidence count by the Census-adjusted number
of screen-detected cases in each year. Finally, we expressed over-
diagnosis as the annual percentage of all lung cancer cases that would
be overdiagnosed, calculated by dividing the Census-adjusted excess-
incidence count by the Census-adjusted overall incidence count in the
presence of screening in each year.
In the microsimulation approach, we used the identical individually
simulated life histories in the presence and absence of screening to
determine the Census-adjusted annual number of overdiagnosed cases
in the general US population between 2018–2040. The percentage of
overdiagnosis among screen-detected cases was calculated by dividing
the Census-adjusted number of overdiagnosed cases by the Census-ad-
justed number of screen-detected cases in each year. The percentage of
overdiagnosis among all cases was calculated by dividing the Census-
adjusted number of overdiagnosed cases by the Census-adjusted overall
incidence count in the presence of screening in each year.
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2.4. Sensitivity analyses
A previous study found that the degree of lung cancer overdiagnosis
varies across histologies [4]. As the MISCAN-lung model incorporates
sex and histology-speciﬁc natural history parameters, our estimates
account for these diﬀerences. To provide insight into these diﬀerences,
we stratiﬁed our lifetime cumulative excess-incidence estimates of the
percentage of screen-detected cancers that are overdiagnosed for sev-
eral separate birth-cohorts by histology and sex.
Furthermore, smoking trends in the general population are diﬀerent
for men and women [8]. Therefore, we also stratiﬁed our estimates of
overdiagnosis in the general US population using the annual excess-
incidence approach and the microsimulation approaches by sex.
3. Results
3.1. Projecting incidence
For each separate birth-cohort, the Census-adjusted annual lung
cancer incidence count would increase when individuals ﬁrst become
eligible for screening (see Fig. 1). As individuals reach the upper age
limit for screening eligibility, there would be a compensatory drop in
incidence. Both these peaks and drops in the Census-adjusted annual
incidence count would be higher for older birth-cohorts than for
younger birth-cohorts. For example, the peak diﬀerence in the Census-
adjusted annual incidence count between screening and no screening
would be +5389 cases for the 1950 cohort compared to +374 cases for
the 1990 cohort.
In the aggregated general US population, the full-scale (i.e. 100%
adherence) introduction of lung cancer screening in 2018 would in-
crease the Census-adjusted annual incidence count in that year from
197,348 to 309,327 (+ 56.7 %). Subsequently, incidence in the pre-
sence of screening would gradually decrease (Fig. 2A). By 2028, the
Census-adjusted annual incidence count in the presence of screening
(212,810 cases in 2028) would approach incidence in the absence of
screening (212,050 cases in 2028). Fig. 2B shows that the projected
Census-adjusted annual incidence count in the presence of screening
would even be lower than in the absence of screening from 2029
onwards (up to -1.0 % in 2036).
3.2. Overdiagnosis estimate using the cumulative excess-incidence approach
As shown in Table 1, the cumulative background incidence rate in
the absence of screening would be higher in older birth-cohorts than in
younger birth-cohorts (1950 cohort: 6206 per 100,000; 1990 cohort:
4157 per 100,000). Also, the percentage of persons ever screened would
be higher in older birth-cohorts (1950 cohort: 15.5 %; 1990 cohort: 2.9
%). Consequently, the rate of screen-detected cases and the rate of
overdiagnosed cases would also be lower in younger birth-cohorts
(1950 cohort: 1414 screen-detected cases and 148 overdiagnosed cases
per 100,000; 1990 cohort: 287 screen-detected cases and 17 over-
diagnosed cases per 100,000). With lifetime follow-up, 10.5 % of
screen-detected cases would be overdiagnosed in the 1950 birth-cohort
compared to 5.9 % in the 1990 birth-cohort. Finally, 2.3 % of all lung
cancer cases would be overdiagnosed in the 1950 birth-cohort com-
pared to 0.4 % of the 1990 birth-cohort.
3.3. Overdiagnosis estimate using the annual excess-incidence approach
In the general US population, the Census-adjusted annual excess-
incidence count would be 2579 cases in 2027 (4.3 % of screen-detected
cases and 1.2 % of all lung cancer cases). By 2028, the Census-adjusted
annual excess-incidence count would have decreased to 760 cases (1.4
% of screen-detected cases and 0.4 % of all lung cancer cases). From
2029 onwards, incidence in the presence of screening would be lower
than incidence in the absence of screening (see Fig. 2B). Therefore,
there would be no annual excess-incidence from 2029 onwards, sug-
gesting that no overdiagnosis would occur between 2029-2040.
3.4. Overdiagnosis using the microsimulation approach
Using the individually simulated life histories in the presence and
absence of screening, the Census-adjusted annual number of over-
diagnosed cases in the general US population in 2018 would be 11,429
(see Fig. 3A). After that, overdiagnosis would gradually decrease to
2851 cases in 2040. Fig. 3B shows the components necessary to express
overdiagnosis as a percentage of screen-detected cases and as a per-
centage of all cases. Similar to the Census-adjusted annual number of
overdiagnosed cases, the Census-adjusted annual number of screen-
detected cases would also decrease, although at a faster rate (see
Fig. 3B). Consequently, the proportion of screen-detected cases that are
overdiagnosed would initially increase from 7.1 % in 2018 to 9.5 % in
2035 (see Fig. 4).
In contrast to the decreasing Census-adjusted annual number of
screen-detected cases, the Census-adjusted overall annual incidence
count in the general population would remain relatively stable after the
initial incidence peak. Combined with the declining Census-adjusted
number of overdiagnosed cases, the percentage of all lung cancer cases
that are overdiagnosed would decrease from 3.7 % of all lung cancer
cases in 2018 to 1.4 % in 2040 (see Fig. 4).
3.5. Sensitivity analyses
Using the cumulative excess-incidence approach, the percentage of
screen-detected cancers that were overdiagnosed was higher for women
(range: 5.7 % in the 1990 cohort to 11.2 % in the 1950 cohort) than for
men (range: 6.1 % in the 1990 cohort to 9.8 % in the 1950 cohort) in
each evaluated birth-cohort except the 1990 cohort (see Supplementary
Fig. 1). This was also the case for the percentage of screen-detected
adenocarcinomas that were overdiagnosed (range across women: 6.3 %
in the 1990 cohort to 12.7 % in the 1950 cohort; range across men: 6.8
% in the 1990 cohort to 10.9 % in the 1950 cohort). Across histologies,
screen-detected adenocarcinomas were most likely to be overdiagnosed
(range: 6.6 % in the 1990 cohort to 11.9 % in the 1950 cohort).
Fig. 1. Census-adjusted annual lung cancer incidence count between
2015–2060 for several US birth-cohorts when implementing lung cancer
screening using the United States Preventive Task Force eligibility criteria in
2018. Results are presented through 2060 to show the lifetime eﬀect of
screening on incidence for several birth-cohorts.
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The proportion of screen-detected squamous cell carcinomas that
were overdiagnosed was higher for men (range: 7.1 % in the 1990
cohort to 10.4 % in the 1950 cohort) than for women (range: 6.4 % in
the 1990 cohort to 9.9 % in the 1950 cohort). The percentage of
overdiagnosed screen-detected small cell lung cancers was low for both
sexes (range: 1.7 % in the 1990 cohort to 2.8 % in the 1950 cohort).
Using the annual excess-incidence approach, the Census-adjusted
number of overdiagnosed cases would still approach zero in 2029 in
both men and women (see Supplementary Fig. 2). Using the micro-
simulation approach, overdiagnosis among screen-detected cases and
all cases was more common among women than men (see
Supplementary Fig. 3). However, time trends were similar to the base-
case analysis.
4. Discussion
4.1. Modeling incidence
To our knowledge, we are the ﬁrst to project the impact of con-
tinuous lung cancer screening on incidence and overdiagnosis for a
Fig. 2. A) Census-adjusted annual lung cancer incidence count in the general United States population between 2015–2040 when fully implementing lung cancer
screening using the United States Preventive Task Force eligibility criteria in 2018. B) Detail of panel A for years.2026–2040.
Table 1
Lung cancer incidence rates, screening eligibility, and overdiagnosis for several separate US birth-cohorts when fully implementing lung cancer screening in 2018
using the United States Preventive Task Force recommendations.
Birth-
cohort
Cumulative incidence
in the absence of
screening a
Percentage of the
cohort ever
screened b
Number of
screen-detected
cases a
Cumulative incidence
in the presence of
screening a
Number of over-
diagnosed cases
a,c
Percentage of screen-
detected cases that would
be overdiagnosed d
Percentage of all cases
that would be
overdiagnosed e
1950 6206 15.5 % 1414 6354 148 10.5 % 2.3 %
1960 5791 13.8 % 1307 5899 108 8.2 % 1.8 %
1970 4665 7.1 % 660 4712 47 7.1 % 1.0 %
1980 4635 5.1 % 492 4666 31 6.2 % 0.7 %
1990 4157 2.9 % 287 4174 17 5.9 % 0.4 %
a Because the absolute size of each birth-cohort is diﬀerent, numbers are expressed as rates per 100,000 persons of the cohort that were alive in 2015.
b For cohorts 1950 and 1960, it is assumed that individuals who would have been eligible before the implementation of screening in 2018 did not receive screening
before 2018.
c Calculated by subtracting the cumulative incidence in the absence of screening from the cumulative incidence in the presence of screening.
d Calculated by dividing the rate of overdiagnosed cases by the rate of screen-detected cases.
e Calculated by dividing the rate of overdiagnosed cases by the cumulative incidence rate in the presence of screening.
Fig. 3. A) Census-adjusted annual number of
overdiagnosed lung cancer cases in the general
US population between 2015–2040 when fully
implementing screening using the United
States Preventive Task Force recommendations
in 2018. Perfect screening adherence was as-
sumed. B) Census-adjusted annual lung cancer
incidence count in the general US population
between 2015–2040 when fully implementing
screening using the United States Preventive
Task Force recommendations in 2018, strati-
ﬁed by mode of detection, and the Census-ad-
justed annual number of overdiagnosed cases.
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multitude of US birth-cohorts as well as for the general US population,
using three diﬀerent methods. Stratiﬁed by birth-cohort, incidence
would increase once individuals reach the lower age threshold for
screening (55 years). This increase is due to the early detection of
prevalent and incident preclinical cases. As individuals within each
cohort pass the upper age threshold for screening (80 years), there
would be a compensatory drop in incidence. To fully account for this
compensatory drop in incidence, the follow-up after screening stops
should be at least as long as the longest lead-time [3]. As we used
lifetime follow-up, we fulﬁll this criterion. We found that the eﬀect of
screening on lung cancer incidence (i.e. both the peak and drop) would
be much larger for older cohorts than for younger cohorts. This can be
explained by reductions in smoking trends [8], due to which younger
birth-cohorts 1) have a lower background risk of getting lung cancer,
and 2) are less often eligible for screening [20,21].
In the aggregated general US population, we projected a large in-
cidence peak upon the implementation of screening in 2018, which
occurs because several cohorts would become eligible for screening in
that year (i.e. cohorts 1938–1963). In most other cancer screening
programs, incidence with screening remains higher than incidence
without screening [22]. However, we found that as lung cancer
screening in the general population stabilizes, annual incidence with
screening would become lower than without screening. This happens
because annual incidence in the general population consists of over-
lapping incidence peaks and drops from diﬀerent birth-cohorts. Even-
tually, the larger incidence drops from older cohorts start to overlap
with the smaller incidence peaks from younger birth-cohorts.
4.2. Estimating overdiagnosis
Using the cumulative excess-incidence approach, we found that
overdiagnosis was much more common in older birth-cohorts than in
younger birth-cohorts. These diﬀerences are also driven by declining
background lung cancer risk and screening eligibility. Due to these
trends, cumulative excess-incidence estimates from closed cohorts are
not generalizable to a broader population. Therefore, existing lung
cancer overdiagnosis estimates from randomized controlled trials are
not representative for a continuous lung cancer screening program in
the general US population. In the general US population, the lack of
annual excess-incidence as a result of these declining smoking trends
would suggest that no overdiagnosis occurs after 2029. However, we
used the microsimulation modeling approach to show that over-
diagnosis would be present in the general US population in each year
since the implementation of screening.
Using the microsimulation approach, the percentage of screen-de-
tected lung cancers in the general US population that would be over-
diagnosed increased between 2018–2040, while the percentage of all
lung cancer cases that would be overdiagnosed decreased in the same
period. The increasing percentage of overdiagnosis among screen-de-
tected cases can be explained by the average age of the pool of
screening-eligible individuals. Over time, this pool will increasingly
consist of elderly individuals because fewer individuals from younger
birth-cohorts become eligible for screening. As overdiagnosis is more
common among elderly individuals (due to limited life expectancy), the
Census-adjusted annual number of overdiagnosed cases decreases at a
slower rate than the Census-adjusted annual number of screen-detected
cases. Therefore, the percentage of screen-detected cases that is over-
diagnosed will increase over time. In contrast, the total Census-adjusted
annual incidence count will remain relatively constant over time due to
growth and aging of the population. Therefore, the percentage of all
lung cancer cases that is overdiagnosed will decrease. These ﬁndings
conﬁrm previous work stating that overdiagnosis estimates across dif-
ferent studies can only be compared when the same denominator is
used (i.e. among screen-detected cases or among all cases) [23]. We add
that using diﬀerent denominators can lead to diﬀerent conclusions re-
garding possible time trends in overdiagnosis.
Our sensitivity analyses show that overdiagnosis estimates diﬀer by
sex and histology. Overdiagnosis was generally most common among
adenocarcinomas and among women. These ﬁndings may be explained
by the preclinical duration of disease, which has been estimated to be
longer for women and for adenocarcinomas. [14]. With a longer pre-
clinical duration, the likelihood of overdiagnosis increases. Conversely,
small cell carcinomas are known to progress quickly, which explains the
lower likelihood of overdiagnosis. Among cases with squamous cell
histology, overdiagnosis was more common in men than in women.
This can be explained by the fact that while the preclinical duration is
similar between men and women, the overall life expectancy for men is
lower [14]. The small diﬀerences between men and women in the 1990
cohort can be explained by the small numbers due to the low back-
ground risk of lung cancer. Diﬀerences in population smoking trends
between men and women did not aﬀect our conclusions regarding the
appropriateness of the annual excess-incidence approach and regarding
time trends in overdiagnosis using the microsimulation approach.
4.3. Considerations for other screening programs
Compared to other cancer screening programs, lung cancer
screening is unique because the main risk factor for lung cancer (i.e.
smoking) reduces over time, which aﬀects not only the background risk,
but also screening eligibility. In most other cancer screening programs,
screening eligibility is only determined by age. Nevertheless, screening
participation rates can still vary over time. Also, background risk may
change over time due to changes in behavioral, lifestyle, and medical
factors. For example, the risk of breast cancer has been related to body
mass index, reproductive behavior, and the use of hormone replace-
ment therapy [24], all of which may change over time. An earlier
theoretical study found that, if breast cancer risk and breast screening
participation rates increase over time, the excess-incidence approach
would overestimate overdiagnosis [25]. Indeed, the background risk of
breast cancer seems to increase over time [23]. Therefore, previous
studies that have applied the excess-incidence approach to a population
Fig. 4. Annual percentage of overdiagnosed lung cancer cases in the United
States between 2018–2040 when fully implementing lung cancer screening
using the United States Preventive Task Force eligibility criteria in 2018. The
percentage of overdiagnosis among screen-detected cases was calculated by
dividing the Census-adjusted number of overdiagnosed cases by the Census-
adjusted number of screen-detected cases in each year. The percentage of
overdiagnosis among all cases was calculated by dividing the Census-adjusted
number of overdiagnosed cases by the Census-adjusted overall incidence count
in the presence of screening in each year.
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setting may have overestimated breast cancer overdiagnosis [26].
4.4. Strengths and limitations
A major strength of our study is the use of the MISCAN-Lung model,
which allows for a comparison of identical full life histories in the ab-
sence and presence of screening. Also, our model can take smoking
trends across birth-cohorts into account. Finally, microsimulation
modeling can assess the eﬀects of many diﬀerent screening strategies.
For example, Han et al. showed that lung cancer overdiagnosis esti-
mates (within a ﬁxed cohort) are sensitive to the eligibility criteria
used, such as screening starting and stopping age, and diﬀerent pack-
years criteria [27]. Nevertheless, using microsimulation modeling to
estimate overdiagnosis can have limitations. Most importantly, con-
structing a model implies making underlying assumptions. Also, some
parameters of microsimulation models, such as the natural history,
must be calibrated. This should be done with great care, as diﬀerent
combinations of parameters can ﬁt the same data [28]. For MISCAN-
Lung, details on calibration and validation have been published pre-
viously [13,14].
4.5. Conclusion
We conclude that it is crucial to use appropriate methods to account
for trends in background cancer risk and screening eligibility when
estimating overdiagnosis in the general population. Lung cancer over-
diagnosis estimates from randomized trials, which are based on the
cumulative excess-incidence approach in a closed cohort with a limited
number of screens, are not generalizable to a screening program in the
general population. Using the annual excess-incidence approach in the
general US population suggests that no overdiagnosis will occur be-
tween 2029-2040. However, this estimate is biased as diﬀerences in
background risk and screening eligibility across cohorts are not taken
into account. Using the microsimulation method, we show that lung
cancer overdiagnosis in the general US population between 2018–2040
will be limited but not nil. Due to trends in background risk and
screening eligibility, overdiagnosis among screen-detected cases will
increase between 2018–2040, while overdiagnosis among all cancer
cases will decrease.
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